Retirement Systems of Alabama Lowers Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Retirement Systems of Alabama trimmed its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 0.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 192,867 shares of the specialty pharmaceutical company’s stock after selling 1,252 shares during the quarter. Retirement Systems of Alabama owned approximately 0.31% of Jazz Pharmaceuticals worth $20,585,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in Jazz Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock worth $776,551,000 after purchasing an additional 84,941 shares in the last quarter. LSV Asset Management raised its stake in shares of Jazz Pharmaceuticals by 1.6% during the 1st quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock worth $286,703,000 after acquiring an additional 37,631 shares in the last quarter. Polaris Capital Management LLC lifted its position in Jazz Pharmaceuticals by 13.0% during the first quarter. Polaris Capital Management LLC now owns 1,432,660 shares of the specialty pharmaceutical company’s stock valued at $172,521,000 after acquiring an additional 165,200 shares during the last quarter. Capital World Investors acquired a new stake in Jazz Pharmaceuticals in the first quarter valued at approximately $171,943,000. Finally, Swedbank AB purchased a new position in Jazz Pharmaceuticals in the second quarter worth $106,936,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.6 %

Shares of JAZZ opened at $113.87 on Friday. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $146.70. The company has a quick ratio of 1.90, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The company has a market capitalization of $7.18 billion, a price-to-earnings ratio of 23.48, a PEG ratio of 1.76 and a beta of 0.58. The stock’s 50-day moving average price is $109.11 and its 200-day moving average price is $113.06.

Analyst Ratings Changes

JAZZ has been the subject of several analyst reports. Royal Bank of Canada decreased their price objective on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating for the company in a report on Thursday, August 1st. Robert W. Baird lowered their price target on Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a report on Thursday, August 1st. The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price objective on the stock. JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research note on Monday, August 19th. Finally, Needham & Company LLC cut their price target on shares of Jazz Pharmaceuticals from $208.00 to $205.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $173.07.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.